Improve Medical Instruments Management
Management criteria checks 3/4
Improve Medical Instruments' CEO is Guanhua Deng, appointed in Oct 2007, has a tenure of 17.25 years. directly owns 15.91% of the company’s shares, worth CN¥269.09M. The average tenure of the management team and the board of directors is 7.7 years and 3.1 years respectively.
Key information
Guanhua Deng
Chief executive officer
CN¥1.3m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 17.3yrs |
| CEO ownership | 15.9% |
| Management average tenure | 7.7yrs |
| Board average tenure | 3.1yrs |
Recent management updates
Recent updates
Lacklustre Performance Is Driving Improve Medical Instruments Co., Ltd.'s (SZSE:300030) 26% Price Drop
Jan 06
Improve Medical Instruments Co., Ltd.'s (SZSE:300030) Price Is Right But Growth Is Lacking After Shares Rocket 28%
Oct 28Improve Medical Instruments Co., Ltd. (SZSE:300030) Held Back By Insufficient Growth Even After Shares Climb 46%
Sep 10Revenues Working Against Improve Medical Instruments Co., Ltd.'s (SZSE:300030) Share Price Following 26% Dive
Jun 06A Look At The Fair Value Of Improve Medical Instruments Co., Ltd. (SZSE:300030)
Jun 04Benign Growth For Improve Medical Instruments Co., Ltd. (SZSE:300030) Underpins Stock's 27% Plummet
Apr 16Improve Medical Instruments Co., Ltd.'s (SZSE:300030) 25% Dip In Price Shows Sentiment Is Matching Revenues
Feb 26CEO
Guanhua Deng (58 yo)
17.3yrs
Tenure
CN¥1,287,600
Compensation
Mr. Guanhua Deng serves as the Chairman and General Manager of Guangzhou Improve Medical Instruments Co. Ltd. since October 26, 2007. Mr. Deng has been with Guangzhou Improve Medical Instruments Co. Ltd.s...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 17.3yrs | CN¥1.29m | 15.91% CN¥ 277.5m | |
| CFO & Deputy GM | 7.7yrs | CN¥491.50k | 0.0095% CN¥ 165.0k | |
| Deputy GM & Non-Independent Director | 7.7yrs | CN¥563.90k | no data | |
| Deputy GM & Non-Independent Director | no data | CN¥562.60k | no data | |
| Board Secretary & Non Independent Director | 3.1yrs | CN¥560.40k | no data | |
| Deputy General Manager | no data | CN¥483.60k | 0.0019% CN¥ 33.8k | |
| Vice President | no data | CN¥240.30k | no data |
7.7yrs
Average Tenure
56.5yo
Average Age
Experienced Management: 300030's management team is seasoned and experienced (7.7 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & GM | 17.3yrs | CN¥1.29m | 15.91% CN¥ 277.5m | |
| Deputy GM & Non-Independent Director | 7.7yrs | CN¥563.90k | no data | |
| Deputy GM & Non-Independent Director | 4.6yrs | CN¥562.60k | no data | |
| Board Secretary & Non Independent Director | 3.1yrs | CN¥560.40k | no data | |
| Independent Director | 4.6yrs | CN¥100.00k | no data | |
| R&D Director and Supervisor | 1.6yrs | no data | no data | |
| Non-Independent Director | 4.6yrs | CN¥382.90k | no data | |
| Non Independent Director | 3.1yrs | no data | no data | |
| Independent Director | 1.6yrs | CN¥52.80k | no data | |
| Independent Director | 1.6yrs | CN¥52.80k | no data | |
| Chairman of the Supervisory Board | 1.6yrs | no data | 0.000020% CN¥ 348.8 |
3.1yrs
Average Tenure
46yo
Average Age
Experienced Board: 300030's board of directors are considered experienced (3.1 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/21 16:38 |
| End of Day Share Price | 2025/01/21 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Improve Medical Instruments Co., Ltd. is covered by 10 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| YANG QIAO | Changjiang Securities Co. LTD. |
| Wenxin Yu | China Investment Securities |
| Yaming Liu | Founder Securities Co., Ltd. |